Lebanon Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Lebanon Breast Cancer Therapeutics Market Analysis

$ 3999

The Lebanon breast cancer therapeutics market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate of xx% from 2022 to 2030 and will reach $xx Bn in 2030. The increasing incidence of breast cancer and ongoing research and development projects for the development of breast cancer treatment drugs are major drivers of Lebanon's breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Sandoz, Ultima, and Johnson & Johnson are some of the leading companies in the Lebanon breast cancer therapeutics market.

ID: IN10LBPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Lebanon AUTHOR: Parul Choudhary

Buy Now

Lebanon Breast Cancer Therapeutics Market Executive Analysis

The Lebanon breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. The World Bank estimates that in Lebanon, the government's healthcare spending represented 11.7% of all government spending in 2020 and was $296 per person in 2019. The economic crisis has made an already acute medical staff, drug, and equipment scarcity in Lebanon's healthcare system much worse. The COVID-19 epidemic has also put more pressure on the healthcare system and raised healthcare costs.

In Lebanon, breast cancer is a serious public health issue. Breast cancer makes up around 30% of all instances of cancer in women, according to the Lebanese National Cancer Registry, making it the most prevalent cancer among Lebanese women. Recent years have seen an increase in the prevalence of breast cancer in Lebanon, with most instances being identified in women over the age of 50. Family history of breast cancer, genetic abnormalities including BRCA1 and BRCA2, obesity, inactivity, and advanced maternal age are risk factors for breast cancer in Lebanon. In order to improve outcomes for women with breast cancer in Lebanon, early detection and treatment are essential.

Due to the economic crisis and a lack of medical personnel, supplies, and equipment, Lebanon has restricted access to advanced breast cancer therapies and technologies such as HER2-targeted therapy and breast-conserving surgery. Access to specialized care for breast cancer is similarly restricted, including genetic testing and counseling.

Market Dynamics

Market Growth Drivers

The market for breast cancer therapeutics will expand in Lebanon as breast cancer is the most prevalent type of cancer that affects women there. The strong trend in ongoing R&D among major market participants engaged in breast cancer treatments would make it possible to meet the demand for effective and precise therapy for breast cancer patients. The Lebanon breast cancer therapeutics market is anticipated to develop rapidly as a result of the tendency toward the introduction of advanced therapies including immunotherapies and targeted therapies.

Market Restraints

In recent years, Lebanon's healthcare system has faced many difficulties, such as a lack of medical staff, supplies, and equipment. Due to the uneven distribution of resources and the lack of standardization in the healthcare system, patients in Lebanon are experiencing trouble getting the best care which could lead to a downfall in Lebanon's breast cancer therapeutics market.

Competitive Landscape

Key Players

Arwan Pharmaceuticals (LBN)
BroadMed (LBN)
Sandoz (LBN)
Ultima (LBN)
Johnson & Johnson
Cipla
Abbott
AbbVie
Merck

Healthcare Policies and Regulatory Landscape

The Ministry of Public Health (MOPH) and third-party payers in Lebanon guarantee financial coverage for cancer treatment in both public and private hospitals. All Lebanese cancer patients have access to therapy thanks to the MOPH's comprehensive coverage of cancer medications. The Lebanese healthcare system has been dealing with a lot of difficulties as a result of the current economic crisis, including a lack of medical staff, medication, and equipment, which has resulted in a lack of standardization in the healthcare system and an unequal allocation of resources. The policies and procedures for reimbursement may also be impacted by this.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.